Poland Green Lights Little Green Pharma
Poland Green Lights Little Green Pharma
Little Green Pharma (ASX:LGP) has announced that its Desert Flame high THC (20%) medicinal cannabis flower product has received Marketing Authorisation in Poland. This marks a significant milestone for the company, providing new opportunities in the rapidly growing medicinal cannabis market in Poland.
Little Green Pharma（ASX: LGP）宣布，其Desert Flame高四氢大麻酚（20％）药用大麻花产品已在波兰获得上市许可。这对公司来说是一个重要的里程碑，为波兰快速增长的药用大麻市场提供了新的机会。
In Poland, Marketing Authorisations are the exclusive pathway for the supply of medicinal cannabis products. Presently, there are ten Marketing Authorisations granted for cannabis flower products with THC content in the range of 18-22%. The wholesale prices of medicinal cannabis flower in this category typically range from $7.50 to $9.50 per gram, while retail prices range between $11 and $15 per gram.
在波兰，上市许可是供应药用大麻产品的唯一途径。目前，四氢大麻酚含量在18-22％之间的大麻花产品已获得十项上市许可。此类药用大麻花的批发价格通常在每克7.50美元至9.50美元之间，而零售价在每克11美元至15美元之间。
LGP's distribution partner in Poland, Medezin S.p. z.o.o., will be responsible for holding the Marketing Authorisation and distributing the Desert Flame product on a white-label basis during the term of their distribution agreement. Medezin is a highly experienced and large-scale pharmaceutical distributor and is a wholly owned subsidiary of Pelion SA, the largest operator in the Polish and Lithuanian healthcare sectors.
LGP在波兰的分销合作伙伴Medezin S.p. z.o.o. 将负责持有营销许可，并在分销协议期限内以白标方式分销Desert Flame产品。Medezin是一家经验丰富的大型药品分销商，是波兰和立陶宛医疗保健领域最大的运营商Pelion SA的全资子公司。
The initial shipment of Desert Flame high THC medicinal cannabis flower from LGP to Poland is scheduled for October 2023. The company views Poland as a highly promising medicinal cannabis market, with a predicted compound annual growth rate (CAGR) of 16%. Factors contributing to this optimistic outlook include Poland's population of 38 million, an import-only supply regime, GP prescribing capability, and no restrictions on the conditions treatable with cannabis.
Desert Flame 高四氢大麻酚药用大麻花定于2023年10月首次从LGP运往波兰。该公司认为波兰是一个非常有前途的药用大麻市场，预计复合年增长率（CAGR）为16％。促成这种乐观前景的因素包括波兰的3,800万人口、仅限进口的供应制度、全科医生的处方能力以及对大麻可治疗的疾病没有限制。
LGP's successful acquisition of Marketing Authorisation in Poland demonstrates the company's preparedness to register additional products in Poland and other jurisdictions with similar barriers to entry.
LGP成功收购了波兰的营销授权，这表明该公司已准备好在波兰和其他具有类似准入壁垒的司法管辖区注册其他产品。
With this latest development, LGP reinforces its position as a significant global exporter of medicinal cannabis. The company's export-led sales strategy is further validated, positioning LGP to capitalize on the increasing demand for medicinal cannabis products in Europe.
凭借这一最新进展，LGP巩固了其作为药用大麻全球重要出口国的地位。该公司以出口为导向的销售战略得到了进一步验证，这使LGP能够利用欧洲对药用大麻产品不断增长的需求。
The grant of Marketing Authorisation in Poland presents a notable opportunity for Little Green Pharma Ltd, expanding its presence in a promising market and enhancing its reputation as a key player in the global medicinal cannabis industry.
在波兰获得上市许可为Little Green Pharma Ltd提供了一个难得的机会，它扩大了其在充满希望的市场中的影响力，并提高了其作为全球药用大麻行业关键参与者的声誉。
